Connect Biopharma Holdings Ltd SEC filings CNTB
Connect Biopharma Holdings Ltd has 196 filings in SEC EDGAR's recent list, going back to Dec 17, 2020. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 3, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 6, 2026 | — |
| 4 | Insider transaction | Oct 1, 2026 | Sep 30, 2026 |
| 4 | Insider transaction | Oct 1, 2026 | Sep 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 4 | Insider transaction | Jul 1, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Jun 2, 2026 | May 29, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 14, 2026 | — |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 1, 2026 | Mar 31, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 1, 2026 | — |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 16, 2026 | Mar 16, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 28, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 26, 2025 | — |
| 144 | Notice of proposed sale | Nov 24, 2025 | — |
| 144 | Notice of proposed sale | Nov 21, 2025 | — |
| 144 | Notice of proposed sale | Nov 18, 2025 | — |
| 144 | Notice of proposed sale | Oct 1, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 21, 2025 | — |
| 144 | Notice of proposed sale | Jun 11, 2025 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 1, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 27, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 27, 2024 | — |
| SC 13D | Ownership over 5% (active) | Feb 13, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Dec 20, 2023 | — |
| 144 | Notice of proposed sale | Dec 18, 2023 | — |
| 144 | Notice of proposed sale | Dec 18, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Dec 14, 2023 | — |
| 144 | Notice of proposed sale | Dec 12, 2023 | — |
| 144 | Notice of proposed sale | Dec 12, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Dec 4, 2023 | — |
| 144 | Notice of proposed sale | Nov 27, 2023 | — |
| 144 | Notice of proposed sale | Nov 27, 2023 | — |
| 144 | Notice of proposed sale | Nov 21, 2023 | — |
| 144 | Notice of proposed sale | Nov 21, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 4, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Feb 13, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Jan 3, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Feb 25, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 25, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 15, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 9, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 7, 2021 | — |
| SC 13D | Ownership over 5% (active) | Mar 29, 2021 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835268
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.